A pilot study into bosentan (Tracleer®) as an immunomodulating agent in patients with Behçet's disease.,Asian Pacific Journal of Allergy and Immunology

当前位置： X-MOL 学术 › Asian Pac. J. Allergy Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A pilot study into bosentan (Tracleer®) as an immunomodulating agent in patients with Behçet's disease.
Asian Pacific Journal of Allergy and Immunology ( IF 2.3 ) Pub Date : 2020-08-23 , DOI: 10.12932/ap-160919-0648
Tim B van der Houwen _{1,

2} , P Martin van Hagen _{1,

2} , Jasper H Kappen ₃ , Robert W A M Kuijpers ₄ , Paul L A van Daele _{1,

2} , Wim A van Dik ₁ , Jan A M van Laar _{1,

2}

Affiliation

Behçet's disease (BD) is an auto-inflammatory vasculitis characterized by aphthous oro-genital ulcers, inflammatory skin changes and uveitis. Treatment is mainly immunosuppressive. Interestingly, elevated endotheline-1 (ET-1) levels suggest a possible beneficial effect of treatment with an ET-1 receptor antagonist.

中文翻译：